Cascadia Drug Development Group
Cascadia Drug Development Group is a Seattle-based, privately held immunology and drug development consulting firm founded in 2016, providing strategic advisory and tactical oversight of therapeutic programs for early-stage biotech, pharma, academic institutions, and venture capital clients through a virtual network of expert affiliates.
- Company typePrivate
- Founded2016
- HeadquartersSeattle, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Cascadia Drug Development Group does
Cascadia Drug Development Group, LLC (CDDG) is a Seattle-based, privately held drug development consulting firm founded in 2016 that provides strategic advisory and hands-on tactical oversight of therapeutic development programs, with a specialization in immunology. The firm functions as a single point of contact for clients needing indication prioritization, pipeline and diligence strategy, biomarker and translational science support, IND preparation, and clinical program design, and it routes work through a curated network of affiliate experts covering protein engineering, toxicology, bioanalytics, PK/PD modeling, bioinformatics, formulation, clinical operations, and regulatory affairs. The core technology is a coordinated consulting framework rather than a software product, supported by strategic partnerships with Vindhya Data Science (bioinformatics and AI), Pharmefex (CMC and manufacturing), Olympic Protein Technologies (protein sciences), and Alpine Institute for Drug Discovery (European translational work), and reinforced by a free autoimmune disease industry report used for thought-leadership lead generation.
CDDG operates a virtual, lean professional-services model that bills through project-based fee-for-service engagements and explicitly leaves room for non-standard partnering structures. It serves a horizontally segmented client base including early-stage and clinical-stage biotechnology companies (e.g., Sonoma Biotherapeutics, Gossamer Bio, Celimmune, Amdax Therapeutics, Orphanon, Denali Therapeutics), pharmaceutical companies (Yuyu Pharma), venture capital investors (Pontifax VC), academic research centers, and non-profit foundations. The leadership team consists of managing Partners Bill Dougall PhD (joined 2020, ex-Amgen, ex-QIMR Berghofer) and Jan L Hillson MD (joined 2024, ex-ZymoGenetics, Momenta, Chemocentryx, Alpine Immune Sciences, Provention Bio), following the May 2024 retirement of Founding Partner Wayne Tsuji. The firm is founder-owned, with no disclosed institutional funding, no parent company, and no subsidiaries, and is currently expanding its affiliate base, most recently in May 2026.
Cascadia Drug Development Group firmographics
Firmographics- Name
- Cascadia Drug Development Group
- Legal name
- Cascadia Drug Development Group, LLC
- Website
- https://thecddg.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Cascadia Drug Development Group is a Seattle-based, privately held immunology and drug development consulting firm founded in 2016, providing strategic advisory and tactical oversight of therapeutic programs for early-stage biotech, pharma, academic institutions, and venture capital clients through a virtual network of expert affiliates.
- Ownership category
- akta.pro rank
Cascadia Drug Development Group industry classification
Industry- Product category
- Drug Development Consulting
- NAICS
- Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy) (HLAAAMAB)
- akta.pro secondary industry
- Companion Diagnostics (CDx) Development & Trial Testing Support (HLAGAEAJ)
Keywords
Where Cascadia Drug Development Group is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Cascadia Drug Development Group business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Drug Development Consulting Services: CDDG provides strategic advisory support and planning/tactical oversight of therapeutic development activities through fee-for-service consulting arrangements. They also welcome discussions around more fully partnering on projects beyond standard fee structures.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Cascadia Drug Development Group product offering
Product offeringCore offering
Cascadia Drug Development Group (CDDG) provides drug development consulting services with deep specialization in immunology. The firm delivers strategic advisory support (indication prioritization, investment diligence, pipeline strategy) and hands-on planning/tactical oversight of therapeutic development activities, integrating quality decisions early in programs to bridge discovery, lead generation, and initial clinical proof of concept. CDDG coordinates an Affiliate network of vetted subject matter experts and serves biotech, pharma, academic, foundation, and investor clients.
Product overview
Cascadia Drug Development Group (CDDG) is a drug development consulting company that provides strategic advisory support and planning/tactical oversight of therapeutic development activities. The company offers a single point of contact for a full range of immunology and drug development consulting expertise, including indication prioritization, investment opportunity diligence, and support spanning from discovery through initial clinical proof of concept. Their core offerings include Drug Development Consulting Services, Immunology Expertise, Translational Science Support, and access to their CDDG Affiliates Network of subject matter experts. They also offer a free Autoimmune Disease Report as a marketing/educational resource.
Differentiator
Problem solved
Functional benefit
Products and services
- Drug Development Consulting Services Strategic advisory support and planning/tactical oversight of therapeutic development activities, including indication prioritization, investment opportunity diligence, pipeline and indication strategy, biomarker plan design, IND filing support, and integration of quality decisions early in programs. Engagements span target rationale and validation, assay development, lead selection, protein engineering, bioinformatics, preclinical pharmacology, formulation, immunogenicity, toxicology, PK/PD, scientific writing, regulatory interactions, and clinical trial design and management for biotech, pharma, academic, foundation, and investor clients.
Quantifiable outcome
- Successfully supported multiple IND filings and regulatory submissions for biotech clients
- +1 more outcomes
Companies that use Cascadia Drug Development Group
Customer profileNamed customers8 records
Segments5 records
Ideal customer profiles5 records
Cascadia Drug Development Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Cascadia Drug Development Group partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core, minor and supporting.
- Vindhya Data SciencecoreCDDG and Vindhya Data Science entered a strategic partnership combining deep drug development knowledge with computational biology expertise. Vindhya provides bioinformatics, data science, machine learning and AI capabilities to help biopharmaceutical companies answer complex questions in drug discovery and development. Both companies share high standards of quality, extensive industry experience, and take a personalized approach with clients.
- Evergreen Bioscience Innovation ClusterminorCDDG joined as a founding member of the Evergreen Bioscience Innovation Cluster, a grant-funded initiative aimed at making Washington State and the Mountain Northwest a hub for life and health science contract research, development, and manufacturing services. CDDG provides strategic input relevant to therapeutic development and leverages its extensive network to help build a robust innovation cluster in the region.
- PharmefexcoreCDDG partnered with Pharmefex to expand the scope of services for clients. Pharmefex specializes in CMC submissions, process and analytical development, manufacturing, GMP compliance, validation, and cost of goods reduction for recombinant proteins, ADCs, monoclonal antibodies, and cell and gene therapy products. The partnership combines CDDG's drug development oversight with Pharmefex's manufacturing and regulatory expertise.
- Olympic Protein TechnologiessupportingOlympic Protein Technologies (OPT) is a contract research organization focused on providing high quality protein science services including construct design, expression, protein production and characterization, biomolecular interaction analysis, and protein engineering services. OPT is led by Michael Wittekind, who also serves as a CDDG affiliate.
- Alpine Institute for Drug Discovery (AiDD)supportingAiDD is a Switzerland-based company focused on translational drug discovery with academic researchers, technology transfer offices and local incubators. Their initial therapeutic focus is immunotherapeutics for oncology and autoimmune/inflammatory diseases, aligning with CDDG's expertise in immunology.
Scale indicators1 record
Recent moves6 records
Expansion highlights5 records
Cascadia Drug Development Group competitors and assessment
Company assessmentDirect peers
- Triangle Insights Group: Triangle Insights is a boutique strategy consulting firm focused on biopharma asset and portfolio strategy, with strong overlap to CDDG's indication strategy and pipeline/diligence support offerings for emerging biotech.
- Camargo Pharmaceutical Services: Camargo provides drug development consulting with particular strength in 505(b)(2) and specialty pharma regulatory pathways. It is comparable to CDDG as a fee-for-service drug development advisor focused on early-to-mid stage programs, though its regulatory niche differs from CDDG's immunology focus.
- Halloran Consulting Group: Halloran provides drug development and regulatory consulting to emerging biotechs and larger pharma, with deep expertise in clinical, quality, and regulatory strategy. Comparable to CDDG in target customer (small-to-mid biotech), service offering (development strategy and oversight), and engagement model.
- Catenion: Catenion is a biopharma strategy consultancy specializing in R&D portfolio and pipeline strategy for pharma and biotech. Comparable to CDDG for strategic advisory on indication prioritization, pipeline architecture, and due diligence for biotech investors.
- Alacrita: Alacrita is a drug development and biotech consulting firm offering therapeutic strategy, due diligence, and clinical/commercial advisory. It competes directly with CDDG in serving small biotechs and academic spin-outs needing translational and development expertise on a project basis.
- Defined Health: Defined Health is a biopharma strategy consulting firm advising biotech and pharma on pipeline strategy, indication prioritization, and asset diligence — overlapping significantly with CDDG's strategic advisory and diligence offerings to similar client profiles.
- Back Bay Life Science Advisors: Back Bay is a life science strategy and transaction advisory firm working with biotech, pharma, and investors on pipeline, financing, and strategic decisions. Comparable to CDDG in serving biotechs and biotech-focused VCs for diligence and pipeline strategy work.
- Kineticos Life Sciences: Kineticos is a life sciences consulting firm offering strategy, commercial, and operational advisory to biotech and pharma. Comparable to CDDG in client base (early-stage to mid biotech) and project-based consulting model, though oriented more toward commercial strategy.
- NDA Partners: NDA Partners is a boutique drug development consulting firm providing expert regulatory, clinical, and CMC advisory to pharma and biotech. It is the closest direct competitor to CDDG, sharing the expert-network model, fee-for-service structure, and focus on IND-enabling and clinical strategy support.
Broad incumbents
- ProPharma Group: ProPharma is a larger pharma consulting and compliance firm offering regulatory, clinical, and quality services across the development lifecycle. It overlaps with CDDG in regulatory and clinical strategy advisory but operates at broader scale and serves more enterprise pharma clients.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Cascadia Drug Development Group social profiles
Digital presenceCascadia Drug Development Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cascadia Drug Development Group leadership team
Management profileNumber of profiles
Profiles2 records
Cascadia Drug Development Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cascadia Drug Development Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cascadia Drug Development Group
What does Cascadia Drug Development Group do?
Cascadia Drug Development Group (CDDG) provides drug development consulting services with deep specialization in immunology. The firm delivers strategic advisory support (indication prioritization, investment diligence, pipeline strategy) and hands-on planning/tactical oversight of therapeutic development activities, integrating quality decisions early in programs to bridge discovery, lead generation, and initial clinical proof of concept. CDDG coordinates an Affiliate network of vetted subject matter experts and serves biotech, pharma, academic, foundation, and investor clients.
Is Cascadia Drug Development Group a public or private company?
Cascadia Drug Development Group is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Cascadia Drug Development Group founded?
Cascadia Drug Development Group was founded in 2016. It employs 11 to 50 people.
Where is Cascadia Drug Development Group based?
Cascadia Drug Development Group is headquartered in Seattle, United States, in the North America region.
How does Cascadia Drug Development Group make money?
One revenue line is on record: drug Development Consulting Services.
Who are Cascadia Drug Development Group's main competitors?
Direct peers on record are Triangle Insights Group, Camargo Pharmaceutical Services, Halloran Consulting Group, Catenion, Alacrita, Defined Health, Back Bay Life Science Advisors, Kineticos Life Sciences and NDA Partners. ProPharma Group is listed as a broad incumbent.
Does Cascadia Drug Development Group have an API?
No public API is recorded for Cascadia Drug Development Group.
What industry is Cascadia Drug Development Group in?
Cascadia Drug Development Group's product category is Drug Development Consulting. Its primary akta.pro industry code is HLAAAMAB, Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy), with a secondary code of HLAGAEAJ, Companion Diagnostics (CDx) Development & Trial Testing Support. Its NAICS code is 5417 and its SIC code is 8731.